In the ever-evolving global landscape of cell therapy development, selecting quality raw materials is crucial for achieving clinical and commercial milestones. In this Innovator Insight article, Kyle Hondorp asks industry experts, Kasey Kime and Lili Belcastro, to share insights into the key factors influencing raw material selection throughout different phases of development. Kyle Hondorp also discusses the Gibco™ Cell Therapy Systems (CTS™) portfolio of fit-for-purpose media and reagents, cell therapy instrumentation, and viral vector systems, which are GMP manufactured, safety tested, and backed by regulatory documentation to support cell and gene therapy developers along their path to commercialization.
提供商 |
賽默飛世爾科技（中國(guó)）有限公司 | 下載次數(shù) |
0次 |
資料大小 |
3.7MB | 資料類型 |
PDF 文件 |
資料圖片 |
-- | 瀏覽次數(shù) |
20次 |
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)
會(huì)員.png)
2
立即詢價(jià)
您提交后，專屬客服將第一時(shí)間為您服務(wù)